Propylpyrazoletriol
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H22N2O3 |
Molar mass | 386.451 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Propylpyrazoletriol (PPT) is a synthetic, nonsteroidal agonist of ERα with 400-fold selectivity over ERβ[1] that is used widely in scientific research to study the function of ERα.[2][3][4] Though originally thought to be highly selective for ERα, PPT has subsequently been found to also act as an agonist of the GPER (GPR30).[5]
See also
References
- ↑ Ottow E, Weinmann H (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 50–. ISBN 978-3-527-62330-3.
- ↑ Plant TM, Zeleznik AJ (15 November 2014). Knobil and Neill's Physiology of Reproduction: Two-Volume Set. Academic Press. pp. 2311–. ISBN 978-0-12-397769-4.
- ↑ Cytoplasmic and Nuclear Receptors—Advances in Research and Application: 2012 Edition. ScholarlyEditions. 26 December 2012. pp. 220–. ISBN 978-1-4649-9741-9.
- ↑ Synthesis of Non-steroidal Estrogen Receptor Proteolysis Targeting Chimeric Molecules (PROTACS). 2008. pp. 11–. ISBN 978-0-549-90990-3.
- ↑ Prossnitz ER, Barton M (May 2014). "Estrogen biology: new insights into GPER function and clinical opportunities". Molecular and Cellular Endocrinology. 389 (1–2): 71–83. doi:10.1016/j.mce.2014.02.002. PMC 4040308. PMID 24530924.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.